Discover
KZR
Kezar Life Sciences, Inc.
7.29
1 x 7.24
1 x 7.41
bid
ask
+
7.29
0.00%
1 @ 04:00 PM
7.37 +0.08 (1.10%)
| Ytd | 15.90% | |
| 1y | 72.75% |
7.27
day range
7.47
5.20
52 week range
11.40
| Open | 7.36 | Prev Close | Low | 7.27 | High | 7.47 | Mkt Cap | 46.99M | |
| Vol | 616.02K | Avg Vol | 108.25K | EPS | -13.12 | P/E | N/A | Forward P/E | -0.62 |
| Beta | 0.22 | Short Ratio | 0.93 | Inst. Own | 63.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 7.44 | 200-d Avg | 7.19 | 1yr Est | 13.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -3.03 | -2.78 | 0.25 | 8.25% |
| 2024-08-13 | 2024-06 | -3.2 | -2.8 | 0.4 | 12.50% |
| 2024-08-13 | 2024-06 | -3.2 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -3.4 | -3 | 0.4 | 11.76% |
| 2024-05-09 | 2024-03 | -3.4 | N/A | N/A | N/A |
| 2024-03-14 | 2023-12 | -3.9 | -3.5 | 0.4 | 10.26% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2024-12-02 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-14 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
| 2024-10-18 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-10-14 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-10-02 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
Profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-11-09 | FOWLER JOHN FRANKLIN | Chief Executive Officer | 436.12K | Conversion of Exercise of derivative security |
| 2023-07-19 | KIRK CHRISTOPHER J | Director | 431.35K | Conversion of Exercise of derivative security |
| 2023-02-05 | MORNINGSIDE VENTURE INVESTMENTS, LTD. | Beneficial Owner of more than 10% of a Class of Security | 5.45M | Sale |
| 2024-07-01 | SCHILLER MARK C | Officer | 33.01K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Adar1 Capital Management, LLC | 1.34M | 8.62M | 18.34% |
| 2024-09-29 | Suvretta Capital Management, LLC | 716.76K | 4.62M | 9.82% |
| 2024-09-29 | Avidity Partners Management, LP | 502.60K | 3.24M | 6.89% |
| 2024-09-29 | Tang Capital Management, LLC | 364.03K | 2.34M | 4.99% |
| 2024-09-29 | Vanguard Group Inc | 274.11K | 1.77M | 3.76% |
| 2024-09-29 | Affinity Asset Advisors, Llc | 251.18K | 1.62M | 3.44% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 187.76K | 1.21M | 2.57% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 76.47K | 492.49K | 1.05% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 35.83K | 230.77K | 0.49% |
| 2024-10-30 | Fidelity Total Market Index Fund | 10.81K | 69.62K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.52K | 54.88K | 0.12% |
| 2024-09-29 | Price (T.Rowe) U.S. Equities Trust | 8.36K | 53.84K | 0.11% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2024-10-30 |